GLP-1 and Mental Health:
What the Evidence Shows

The link between obesity and mental health

The relationship between obesity and mental health is complex and bidirectional. People living with obesity are significantly more likely to experience depression, anxiety, low self-esteem and social isolation. Conversely, mental health conditions can contribute to weight gain through emotional eating, reduced physical activity and the side effects of psychiatric medications.

In the UK, data from the Health Survey for England shows that adults with obesity are approximately 55 per cent more likely to develop depression than those of a healthy weight. The psychological burden of weight stigma — discrimination and negative attitudes directed at people because of their weight — further compounds mental health difficulties.

This context is important when considering how weight loss medications affect mental health: for many patients, effective weight management represents a significant opportunity to improve psychological wellbeing.

Positive mental health effects of GLP-1 therapy

The majority of clinical trial data and patient-reported outcomes suggest that GLP-1 therapy is associated with improvements in mental health and quality of life.

Quality of life improvements

The STEP clinical trial programme measured patient-reported outcomes using validated questionnaires. Patients taking semaglutide (Wegovy) reported significant improvements in:

• Physical functioning: Easier mobility, less pain, greater energy
• Body image satisfaction: Improved self-perception and confidence
• Social engagement: Greater willingness to participate in social activities
• Overall quality of life: Higher scores on the Impact of Weight on Quality of Life (IWQOL-Lite) questionnaire

Self-confidence and body image

Significant weight loss often brings a profound improvement in how patients feel about themselves. Many report feeling more confident in social and professional settings, being more willing to engage in physical activities, and experiencing a greater sense of control over their health.

Research published in the journal Obesity found that patients who achieved 10 per cent or more weight loss on semaglutide reported clinically meaningful improvements in depression and anxiety symptom scores, suggesting that the mental health benefits are dose-responsive and linked to the degree of weight reduction.

Reduced food preoccupation

One of the most striking psychological effects reported by patients on GLP-1 therapy is a reduction in food-related thoughts and preoccupation. This has been described variously as the quieting of constant hunger or the reduction of obsessive thinking about the next meal. For individuals who have struggled with their weight for years, this change can be psychologically liberating.

Research suggests this effect is mediated by semaglutide's action on brain reward centres, reducing the dopaminergic response to food cues. Some patients describe it as a fundamental shift in their relationship with food.

Reports of suicidal ideation: what happened

In 2023, media reports raised concerns about a possible link between GLP-1 medications and suicidal ideation (thoughts of self-harm or suicide). This prompted formal safety reviews by both the European Medicines Agency (EMA) and the UK's MHRA.

The EMA review (2023–2024)

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a thorough review of all available evidence, including clinical trial data, post-marketing adverse event reports and epidemiological studies. Their conclusion, published in 2024, was that the available evidence did not support a causal link between GLP-1 receptor agonists and suicidal or self-harming thoughts.

The PRAC noted that:

• In clinical trials, rates of suicidal ideation were similar in GLP-1 treatment groups and placebo groups
• Post-marketing reports were difficult to interpret because many patients had pre-existing mental health conditions or were taking other medications known to affect mood
• The overall reporting rate was consistent with background rates in the population being treated

The MHRA position

The MHRA has aligned with the EMA's findings and continues to monitor the situation through the Yellow Card Scheme. Their position as of 2026 is that no causal relationship has been established between GLP-1 medications and suicidal ideation. However, they recommend:

• Healthcare professionals should be aware of these reports
• Patients should be asked about their mental health during routine consultations
• Any new or worsening psychological symptoms should be reported via the Yellow Card Scheme
• Patients should be encouraged to seek help if they experience thoughts of self-harm

Potential psychological challenges

While most patients experience positive mental health effects, significant weight loss can also bring unexpected psychological challenges. Being aware of these can help patients and healthcare providers address them proactively.

Identity and self-perception

For people who have been overweight for much of their lives, rapid weight loss can trigger an identity shift that is not always comfortable. Some patients report:

• Difficulty reconciling their physical appearance with their internal self-image
• Feeling like a different person, which can be disorienting
• Being unsure how to present themselves socially
• Unexpected grief for aspects of their previous identity

Relationship changes

Significant weight loss can affect interpersonal relationships in ways that are not always positive:

• Shifts in relationship dynamics with partners who may feel threatened or unsettled
• Changes in friendships that were built around shared eating habits
• Increased attention (wanted or unwanted) from others
• Family members making uncomfortable comments about appearance

Excess skin and body dissatisfaction

Rapid or substantial weight loss can result in excess skin, which may cause a new form of body dissatisfaction. Some patients find that while they are healthier and lighter, they are still unhappy with their appearance due to loose skin, particularly around the abdomen, arms and thighs. This can affect self-confidence and intimate relationships.

Anxiety about weight regain

Awareness that weight regain is common after stopping GLP-1 therapy can create anxiety about the sustainability of results. Patients may worry about whether they will need to take the medication indefinitely and what will happen if supply is disrupted or they cannot afford continued treatment.

GLP-1 medications and emotional eating

Emotional eating — using food to cope with negative emotions such as stress, sadness, boredom or loneliness — is a significant contributor to weight gain and difficulty maintaining weight loss. There is growing evidence that GLP-1 medications may help break this pattern.

Semaglutide's effects on brain reward circuits appear to reduce the reward value of food, which may diminish the drive to eat for emotional comfort. Some patients report that the compulsive quality of emotional eating is significantly reduced while on medication.

However, it is important to note that GLP-1 medications do not address the underlying emotional triggers. If food has been a primary coping mechanism, patients may need to develop alternative strategies for managing emotions. Psychological support, including cognitive behavioural therapy (CBT), can be valuable alongside pharmacological treatment.

GLP-1 medications and eating disorders

The relationship between GLP-1 therapy and eating disorders requires careful consideration. GLP-1 medications are not indicated for and should not be used to treat eating disorders such as anorexia nervosa, bulimia nervosa or binge eating disorder.

However, there is emerging interest in the potential role of GLP-1 agonists in binge eating disorder (BED), given their effects on appetite and food reward. Early research suggests that semaglutide may reduce binge-eating episodes, but this is not yet an approved indication and should only be explored within specialist eating disorder services.

Patients with a history of eating disorders should inform their prescriber before starting GLP-1 therapy. The dramatic appetite suppression and altered relationship with food could potentially trigger or exacerbate disordered eating patterns in vulnerable individuals.

Mental health monitoring during treatment

Given the complex relationship between weight, body image and mental health, ongoing monitoring is important throughout GLP-1 therapy.

What your prescriber should ask about

• Changes in mood, including new or worsening depression or anxiety
• Changes in sleep patterns
• Changes in social engagement or withdrawal
• Thoughts of self-harm (however unlikely)
• Relationship changes related to weight loss
• Body image concerns, including satisfaction with physical changes
• Eating patterns and any signs of disordered eating

What you should report

Tell your GP or prescriber about:

• Persistent feelings of sadness, hopelessness or worthlessness
• Increased anxiety that does not improve
• Loss of interest in activities you previously enjoyed
• Difficulty sleeping or sleeping too much
• Any thoughts of self-harm or suicide
• Significant distress about your changing body
• Concerns about your relationship with food

Practical advice for supporting mental health on GLP-1 therapy

• Maintain social connections: Weight loss can change social dynamics. Proactively maintain relationships and communicate openly with those close to you.
• Set realistic expectations: Understand that weight loss is gradual and that not every day will feel like progress. Focus on health improvements, not just the number on the scales.
• Stay physically active: Regular exercise has well-established benefits for both physical and mental health. Even moderate activity can significantly improve mood.
• Eat nutritiously: A well-balanced diet supports both physical and mental wellbeing. Avoid excessively restrictive eating, which can worsen mood.
• Seek professional support: If you are struggling psychologically, ask your GP about counselling or psychological therapy. This is not a sign of weakness but a sensible part of comprehensive health care.
• Be patient with yourself: Adjusting to a changing body and a new relationship with food takes time. Give yourself permission to work through the transition gradually.

Frequently asked questions